174 related articles for article (PubMed ID: 35261806)
1. Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.
Espinoza I; Kurapaty C; Park CH; Vander Steen T; Kleer CG; Wiley E; Rademaker A; Cuyàs E; Verdura S; Buxó M; Reynolds C; Menendez JA; Lupu R
Am J Cancer Res; 2022; 12(2):839-851. PubMed ID: 35261806
[TBL] [Abstract][Full Text] [Related]
2. Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α
Espinoza I; Yang L; Steen TV; Vellon L; Cuyàs E; Verdura S; Lau L; Menendez JA; Lupu R
Aging (Albany NY); 2022 Feb; 14(3):1200-1213. PubMed ID: 35148282
[TBL] [Abstract][Full Text] [Related]
3. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
4. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.
Haque I; Mehta S; Majumder M; Dhar K; De A; McGregor D; Van Veldhuizen PJ; Banerjee SK; Banerjee S
Mol Cancer; 2011 Jan; 10():8. PubMed ID: 21232118
[TBL] [Abstract][Full Text] [Related]
5. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis.
Huang YT; Lan Q; Lorusso G; Duffey N; Rüegg C
Oncotarget; 2017 Feb; 8(6):9200-9215. PubMed ID: 27911269
[TBL] [Abstract][Full Text] [Related]
6. Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma.
Dobroff AS; Wang H; Melnikova VO; Villares GJ; Zigler M; Huang L; Bar-Eli M
J Biol Chem; 2009 Sep; 284(38):26194-206. PubMed ID: 19632997
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells.
Chen N; Leu SJ; Todorovic V; Lam SC; Lau LF
J Biol Chem; 2004 Oct; 279(42):44166-76. PubMed ID: 15308622
[TBL] [Abstract][Full Text] [Related]
8. The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.
Menendez JA; Vellon L; Espinoza I; Lupu R
Oncoscience; 2016; 3(7-8):242-257. PubMed ID: 27713913
[TBL] [Abstract][Full Text] [Related]
9. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
[TBL] [Abstract][Full Text] [Related]
10. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer.
Mayer S; Erbes T; Timme-Bronsert S; Jaeger M; Rücker G; Kuf F; Stickeler E; Gitsch G; Hirschfeld M
Oncol Lett; 2017 Aug; 14(2):2334-2340. PubMed ID: 28789451
[TBL] [Abstract][Full Text] [Related]
12. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
Li B; Huang L; Ruan J
Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
[TBL] [Abstract][Full Text] [Related]
13. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
14. The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis.
Haque I; De A; Majumder M; Mehta S; McGregor D; Banerjee SK; Van Veldhuizen P; Banerjee S
J Biol Chem; 2012 Nov; 287(46):38569-79. PubMed ID: 23027863
[TBL] [Abstract][Full Text] [Related]
15. CYR61 confers chemoresistance by upregulating survivin expression in triple-negative breast cancer.
Kim H; Son S; Ko Y; Lim H; Lee J; Lee KM; Shin I
Carcinogenesis; 2024 Mar; ():. PubMed ID: 38446998
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel integrin alpha 6 beta 1 binding site in the angiogenic inducer CCN1 (CYR61).
Leu SJ; Liu Y; Chen N; Chen CC; Lam SC; Lau LF
J Biol Chem; 2003 Sep; 278(36):33801-8. PubMed ID: 12826661
[TBL] [Abstract][Full Text] [Related]
17. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
18. CCN1/Cyr61 Is Required in Osteoblasts for Responsiveness to the Anabolic Activity of PTH.
Zhao G; Kim EW; Jiang J; Bhoot C; Charles KR; Baek J; Mohan S; Adams JS; Tetradis S; Lyons KM
J Bone Miner Res; 2020 Nov; 35(11):2289-2300. PubMed ID: 32634285
[TBL] [Abstract][Full Text] [Related]
19. Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.
Wu M; Yuan K; Lyu S; Li Y
World J Surg Oncol; 2022 Jun; 20(1):214. PubMed ID: 35751103
[TBL] [Abstract][Full Text] [Related]
20. Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.
Habel N; Vilalta M; Bawa O; Opolon P; Blanco J; Fromigué O
Oncogene; 2015 Jun; 34(24):3207-13. PubMed ID: 25065593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
